U.S. markets rise on hopes of a quick government reopening

U.S. indices finished the session mixed but tilted positive: the S&P 500 gained 0.21% to a one-week high, the Dow Jones rose 1.18% to a one-and-a-half-week high, and the Nasdaq 100 slipped 0.31%. December E-mini S&P futures added 0.26% while E-mini Nasdaq futures fell 0.23%. The main fuel was a political turn: after the Senate voted for a temporary continuing resolution to fund the government, traders are pricing a swift passage through the House and a quick presidential signature. With cash Treasuries closed for Veterans Day, equity volumes were subdued, but risk appetite broadened.

The mere progress on temporary funding removes a tail of political uncertainty. The market immediately recalibrates premia: a greater willingness to take cyclical risk, but without euphoria. This explains how rising Dow and S&P 500 can coexist with a softer Nasdaq 100: the long-running market leaders—chips and AI-linked names—looked weaker on the day.

AI-exposed stocks took a hit after headlines about a data-center delay at CoreWeave and trimmed expectations, triggering a double-digit drop there and a ripple across “AI-infra.” Additional negative sentiment came from reports of a sizable stake sale in Nvidia by a former strategic investor, encouraging profit-taking in the group. The scoreboard showed declines in MU, MRVL, and LRCX, with weakness spreading to ARM, AMD, AMAT, and KLAC, and pressure on heavyweights AVGO, ASML, INTC, and MCHP. This is not a tectonic shift so much as hot money exhaling on fresh news; still, the tactical reassessment in chips happened.

ADP’s snapshot stood out: over the four weeks to October 25 the private sector was trimming jobs on average, pointing to a cooling labor market. The NFIB small-business optimism index slipped to a six-month low at 98.2, below expectations. Together these signals lean toward a softer rate path. Fed-funds pricing reflects an elevated chance of another 25 bp cut at the December 9–10 meeting. It’s not a verdict on growth so much as the passing of peak policy tightness and a normalization in labor demand.

December 10-year T-notes rose by 11 ticks, in tune with softer labor signals and a cooling small-business backdrop. Gains were capped as shutdown risk ebbed and with it some “safe-haven” demand. European yields drifted lower in sympathy: the 10-year Bund around 2.658%, and the UK 10-year slipped to a two-week low near 4.374% into the close. ECB commentary stayed neatly neutral: current levels look appropriate, and decisions will remain strictly data-dependent.

Europe added support with Euro Stoxx 50 up more than a percent, reinforcing global risk appetite. Asia was mixed, with China correcting after local highs and Japan a shade lower. For the U.S., that means no external brake, but also no turbo boost from the region.

As AI narratives cooled, rotation favored pharma and managed care. Leaders included a double-digit jump in Viatris, strong sessions for Moderna and Merck, and notable gains in Amgen, Pfizer, Elevance Health, Gilead, Cigna, Bristol-Myers, Centene, and Regeneron. The news tape was busy: Surmodics surged after a court declined to block its deal with GTCR, RealReal rallied on a higher full-year revenue outlook, Paramount Skydance advanced on a new cost-cut plan, while upgrades helped Viasat and Linde and constructive guidance lifted FedEx. The flip side was continued pressure across parts of the chip complex and adjacent equipment makers.

With the political tail risk shorter and labor and small-business data softening at the margin, the market is ready to re-risk, but selectively. Earnings season provided supportive fundamentals, with the majority of companies beating and aggregate profit growth well above summer expectations. Even so, stretched positioning in the tech favorites keeps the group sensitive to negative headlines, so expect ongoing intraday volatility across chips and AI infrastructure.

The mosaic favors tactical diversification. Some flows are clearly rotating into high-quality defensives—big pharma, insurers, stable cash-flow franchises where multiples are grounded and beta is moderate. Fully exiting growth tech looks premature: the AI monetization arc remains alive, but demands tighter risk discipline and entries after shakeouts. In rates, a window is open to stair-step into duration, cautiously. The market already prices easier policy, so each new dovish data point surprises prices less. The near-term test of resilience is straightforward: House passage of the CR, the next macro prints, and pre-meeting Fed rhetoric.

The market got a rare breather: political noise is fading, macro signals are gentler, and earnings season is supportive. In this setup, indices can grind higher via breadth and a rotation into undervalued quality pockets. But the leadership cluster in AI and semis remains jumpy, which is exactly where short-term opportunities will emerge to buy dips with disciplined stops. The thin line between hopes for a swift government reopening and realism on rates and labor demand is the main storyline for the days ahead.